What question did this study set out to answer?

To identify and characterize psychiatric adverse events associated with the GLP-1 receptor agonists semaglutide, liraglutide, and tirzepatide using European pharmacovigilance data.

January 24, 2024International Journal of Clinical PharmacyOpen Access

Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database

View Full Paper

Ask AI

Bookmark

Authors

MTMansour TobaiqyUniversity of Jeddah HEHajer ElkoutUniversity of Tripoli

Discussion

Member takes

Implication

Pharmacovigilance analysis finds psychiatric adverse events in 1.2% of GLP-1 receptor agonist safety reports, highlighting rare but severe risks including suicidal ideation and fatal outcomes.

Key Points

To identify and characterize psychiatric adverse events associated with the GLP-1 receptor agonists semaglutide, liraglutide, and tirzepatide using European pharmacovigilance data.
Analyzed all individual case safety reports for semaglutide, liraglutide, and tirzepatide submitted to the EudraVigilance database between January 1, 2021, and May 30, 2023.
Evaluated reported patient demographics and psychiatric event profiles using descriptive statistics across 31,444 total adverse event reports.
Identified 372 reports with psychiatric adverse events (1.18% of 31,444 total reports) detailing 481 events, led by depression (n = 187; 50.3%), anxiety (n = 144; 38.7%), and suicidal ideation (n = 73; 19.6%).
Observed that females accounted for 65% (n = 242) of psychiatric reports, while 11 life-threatening outcomes occurred (7 with semaglutide, 4 with liraglutide).
Documented 9 fatal outcomes (8 associated with liraglutide, 1 with semaglutide) resulting from completed suicide attempts and depression, occurring predominantly in males (8 of 9).

Cite This Study

Tobaiqy et al. (2024) studied this question.

synapsesocial.com/papers/69fb64c96d730ca589dd5450 https://doi.org/10.1007/s11096-023-01694-7

View Full Paper

Ask AI

Bookmark

Implication

Pharmacovigilance analysis finds psychiatric adverse events in 1.2% of GLP-1 receptor agonist safety reports, highlighting rare but severe risks including suicidal ideation and fatal outcomes.

Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database

Discussion

Member takes

Implication

Key Points

Cite This Study

Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider